Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual CD33/CLL1 CAR T in R/R AML
NCT05248685Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLL1-CD33 compound CAR T cells in acute myeloid leukemia (AML), sponsored by Beijing Boren Hospital. Primary endpoints: Dose Limiting Toxicity at 21 days and Incidence and Severity of Adverse Events at 30 days. Planned start Feb 2022; status: withdrawn.
02
Drugs
CLL1-CD33 compound CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05248685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248685.